AGAleksandra S. Gurskaya

Aleksandra S. Gurskaya

*This is an algorithmically generated author record based on publicly available information.

Aleksandra S. Gurskaya has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tactics of neonatal surgical treatment of uterine appendage torsion in newborns

    by Elena V. Sibirskaya, Tatiana S. Tikhonova, Alexandra S. Gurskaya, Ekaterina V. Ekimovskaya, Rimir R. Baiazitov, Liubov Yu. Smolik, Alina A. Bogacheva, Roman A. Akhverdian, Е. В. Сибирская, Т. С. Тихонова, et al.

    Introduction. Antenatal torsion of the uterine adnexa remains a challenging diagnostic entity in contemporary perinatal medicine. This is due to the rarity of the condition, the absence of pathognomonic sonographic criteria, and the lack of unified clinical management protocols. Materials and methods. The presented clinical cases describe rare instances of antenatal torsion of the uterine adnexa in newborns. The key diagnostic findings were obtained through prenatal ultrasound examination, which revealed adnexal mass lesions. The diagnosis was subsequently confirmed intraoperatively and by pathological examination. Both patients underwent laparoscopic surgical treatment with histological verification of ovarian tissue necrosis. Results. In both cases, patient survival was achieved; however, the adnexal structures involved in the torsion were nonviable due to the development of tissue necrosis. Conclusion. The presented clinical cases demonstrate the need for further accumulation of experience, systematic data collection, and analysis to establish a consensus-based approach to the diagnosis and management of this condition. Such efforts will not only improve long-term outcomes but also enhance the potential for fertility preservation in affected patients, which is a critical aspect of their future health and reproductive potential. Long-term follow-up and data analysis may form the basis for developing more accurate and effective treatment strategies for antenatal torsion. Contribution: Sibirskaya E.V., Gurskaya A.S. — research concept and design; Tikhonova T.S., Ekimovskaya E.V., Baiazitov R.R. — data analysis, development of treatment tactics, validation; Smolik L.Yu., Bogacheva A.A., Akhverdian R.A. — writing the text; Sibirskaya E.V., Gurskaya A.S. — editing the text. All co-authors — approval of the final version of the article, responsibility for the integrity of all parts of the article. Acknowledgments. The study had no sponsorship. Conflict of interest. The authors declare no conflict of interest. Received: January 15, 2026Accepted: February 10, 2026Published: February 27, 2026

  • Intraoperative classification to predict the development of post-resection short bowel syndrome in children

    by A.S. Gurskaya, R.R. Baiazitov, E.V. Ekimovskaya, S.N. Zorkin, E.YU. Dyakonova, I.V. Karnuta, M.A. Sulavko, F.S. Piloyan, A.S. Chernyavskaya, D.M. Akhmedova, et al.

    Post-resection short bowel syndrome (SBS) in children occurs after extensive resection of various sections of the gastrointestinal (GI) tract and manifests as chronic intestinal failure with the inability to achieve enteral autonomy. Existing classification options for SBS in children are difficult to apply in practice and do not contain information about the prognosis for the development of SBS in a particular patient. Objective. To design the intraoperative classification for predicting the development of post-resection SBS in children. Patients and methods. This study included the results of treatment of 80 children after resection of various sections of the GI tract. Based on these results, the intraoperative classification was designed to predict the development of post-resection SBS.In the group of children with extensive resections (n = 42), a statistical analysis of SBS development was performed depending on the extent and location of the resections performed, as well as the combination of resections in various sections of the GI tract in accordance with the proposed classification. Results. The classification is based on the lesion anatomical site, the extent of resection, and the presence or absence of the ileocecal angle. When comparing the development of SBS depending on the resection of the jejunum, ileum, or colon, more than 90% of patients had this disease after resection of more than 2/3 of the jejunum, and 100% of patients had SBS after resection of more than 2/3 of the colon. Conclusion. The designed intraoperative classification allows the diagnosis to be formulated in such a way that surgeons and pediatricians can understand the extent of resection performed in each individual child and predict the development of postresection SBS. Key words: intraoperative classification of short bowel syndrome, newborns, residual bowel length, extensive bowel resection, parenteral nutrition, short bowel syndrome, chronic intestinal failure, enteral autonomy

  • Open Access

    Diagnostics and treatment of meconium ileus in newborns

    by Felix S. Piloyan, Aleksandra S. Gurskaya, Elena Yu. Dyakonova

    Introduction. Meconium ileus is a disease characterized by the formation of thick, viscous meconium in the lumen of the small intestine with the development of low obstructive intestinal obstruction in newborns. Impaired meconium formation in children with cystic fibrosis is associated with a mutation of the CFTR gene, the development of apical dehydration of the secretory epithelium of the intestinal wall and excretory dysfunction of the pancreas. The aim of the review: to identify the leading mechanisms of formation of meconium ileus in newborn children to optimize its treatment. A review of the literature on the topic meconium ileus. In premature newborns, the development of obstructive intestinal obstruction is associated not only with the presence of dense meconium, but also with immaturity of the motor function of the gastrointestinal tract. Hyperechogenic masses in the intestinal lumen, calcifications in the abdominal cavity, dilation of intestinal loops, and free fluid in the abdominal cavity according to prenatal ultrasound indicate a high probability of cystic fibrosis in the fetus, which requires genetic counselling parents. One of the therapeutic and diagnostic methods for meconium ileus is the setting of a hypertensive enema with a water-soluble hyperosmolar contrast agent. This tactic being acceptable for use in simple forms of meconium ileus as a conservative therapy is effective in 25% of cases. Complicated forms of meconium ileus are characterized by the presence of secondary atresia, isolated inversion of the small intestine, severe ischemia or intestinal necrosis. In severe cases, meconium peritonitis develops simultaneously with perforation of the intestinal wall. Surgical methods for the treatment of simple and complicated forms of meconium ileus include washing meconium from the intestine with the imposition of primary anastomosis, alternative low-traumatic operations (enterotomy), as well as various options for stoma operations. However, a protocol for the treatment of meconium ileus has not yet been developed (including patients with cystic fibrosis). Difficulties remain in choosing the method of surgical correction of the meconium ileus of premature infants.


  • Open Access

    Features of the diagnostics and surgical treatment of necrotizing enterocolitis

    by Aleksandra S. Gurskaya, Ekaterina V. Ekimovskaya, Rimir R. Bayazitov, Олег Николаевич Наковкин, Сергей Николаевич Зоркин, Elena Yu. Dyakonova, Мария Александровна Сулавко, Инна Викторовна Карнута, Анна Алексеевна Клепикова, Feliks S. Piloyan, et al.

    Introduction. Necrotizing enterocolitis (NEC) is one of the common causes for abdominal surgery in newborns and infants over he first months of life with a high mortality rate (23.5%), increased in case of surgery to 67%. Materials and methods. We compared premature (n = 25) and full-term (n = 22) newborns operated for NEC complications (laparotomy, resection of necrotized sections of the intestine, intestinal stoma). Also, we evaluated the results of treatment of infants with intestinal stoma after surgical NEC (n = 110, groups 1, 2 and 3). Results. Full-term cases with congenital heart defects are at risk of surgical NEC (p < 0.05). Subtotal and total forms of NEC are associated with lethal outcomes up to 100% in both premature and full-term infants. It is necessary to preserve the ileocecal angle; length measuring of the remaining intestine along the mesenteric edge helps to predict further risks: 60 cm and less leads to 80–100% of post-resection short bowel syndrome. Conclusion. NEC in full-term newborns is due to its hypoxic nature and impaired mesenteric perfusion (congenital heart defects). Surgical NEC can occur without typical symptoms (“covered perforation”), the discrepancy between the clinical and radiographic picture may indicate to subtotal or total intestinal necrosis with up to 100% of lethal outcomes.

  • Open Access

    Somatostatin analog (octreotide) and sirolimus immunosuppressive therapy in the treatment of chyloperitoneum and chylothorax in newborns and infants

    by A Gurskaya, M Sulavko, E Ekimovskaya, R Bayazitov, O Nakovkin, I Karnuta, A Klepikova, D Akhmedova, R Hagurov, G Sagoyan

    Background: Chyloperitoneum (CP) and chylothorax (CT) are rare conditions that have a high mortality rate and unclear treatment options. Their incidence in neonates ranges from 1 in 20000 to 1 in 187000 live births. This study aims to evaluate the effectiveness of synthetic somatostatin analog (octreotide) and sirolimus therapy in treating chylous pleural and peritoneal collections in newborns and infants. Methods: We conducted a retrospective analysis of 10 children with either chylothorax or chyloperitoneum, treated in our department between 2018 and 2023. The study was approved by the Local Independent Ethics Committee of The National Medical Research Center of Children's Health, under Protocol №7, dated 11 May 2023. The parents voluntarily signed an informed consent form for the off-label use of the drug. We reviewed the medical records for demographic information, clinical presentation, management, and outcome. Results: Our study looked at patients aged between 0 and 5.5 months, with seven cases of chyloperitoneum and three cases of chylothorax. We initially used octreotide, which was then switched to sirolimus if there was no improvement. Octreotide was effective in five children after 10-18 days of treatment, while the effect of sirolimus was observed 8-14 days after starting treatment. One patient, who had a history of a giant omphalocele with primary closure, experienced complications after 8 weeks of sirolimus therapy, including bilateral knee arthritis, leukopenia, and lymphopenia. Fortunately, there were no fatal outcomes. Conclusion: Sirolimus therapy is effective in treating newborns with chylothorax or chyloperitoneum, with a low risk of complications even in those cases not responding to octreotide therapy. It is recommended that octreotide therapy should not exceed 10 days, after which sirolimus can be prescribed.

  • Open Access

    Somatostatin analog (octreotide) and sirolimus immunosuppressive therapy in the treatment of chyloperitoneum and chylothorax in newborns and infants

    by Aleksandra Gurskaya, Mariya Sulavko, Ekaterina Ekimovskaya, Rimir Bayazitov, Oleg Nakovkin, Inna Karnuta, Anna Klepikova, Dinara Akhmedova, Ruslan Hagurov, Garik Sagoyan, et al.

    Background: Chyloperitoneum (CP) and chylothorax (CT) are rare conditions that have a high mortality rate and unclear treatment options. Their incidence in neonates ranges from 1 in 20000 to 1 in 187000 live births. This study aims to evaluate the effectiveness of synthetic somatostatin analog (octreotide) and sirolimus therapy in treating chylous pleural and peritoneal collections in newborns and infants. Methods: We conducted a retrospective analysis of 10 children with either chylothorax or chyloperitoneum, treated in our department between 2018 and 2023. The study was approved by the Local Independent Ethics Committee of The National Medical Research Center of Children's Health, under Protocol №7, dated 11 May 2023. The parents voluntarily signed an informed consent form for the off-label use of the drug. We reviewed the medical records for demographic information, clinical presentation, management, and outcome. Results: Our study looked at patients aged between 0 and 5.5 months, with seven cases of chyloperitoneum and three cases of chylothorax. We initially used octreotide, which was then switched to sirolimus if there was no improvement. Octreotide was effective in five children after 10-18 days of treatment, while the effect of sirolimus was observed 8-14 days after starting treatment. One patient, who had a history of a giant omphalocele with primary closure, experienced complications after 8 weeks of sirolimus therapy, including bilateral knee arthritis, leukopenia, and lymphopenia. Fortunately, there were no fatal outcomes. Conclusion: Sirolimus therapy is effective in treating newborns with chylothorax or chyloperitoneum, with a low risk of complications even in those cases not responding to octreotide therapy. It is recommended that octreotide therapy should not exceed 10 days, after which sirolimus can be prescribed.

  • Open Access

    Diagnosis and treatment of lymphatic malformations: experience of the surgical department for newborns and infants

    by Aleksandra S. Gurskaya, Мария Александровна Сулавко, Rimir R. Bayazitov, Ekaterina V. Ekimovskaya, Олег Николаевич Наковкин, Инна Викторовна Карнута, Анна Алексеевна Клепикова, Garik B. Sagoyan, Руслан Асланович Хагуров, Андрей Петрович Фисенко

    Introduction. Lymphatic malformations (LM) are a congenital pathology of lymphatic vessels that arose during embryogenesis. The relevance of the research topic is due to the rarity, variety of clinical manifestations, and the lack of clinical recommendations for treatment. Aim. To evaluate our experience of surgical and conservative treatment of LM in the surgical department for newborns and infants. Materials and methods. We performed a retrospective analysis of infants with various forms of LM treated at our department from 2017 to 2022. The study protocol was approved by the local ethics committee. The patients’ parents gave written voluntary informed consent to participate in the study. Results. Depending on the form of a LM, the infants underwent conservative therapy, sclerotherapy or surgical resection of the LM. Conclusions. Genetic tests for the spectrum of overgrowth syndromes are necessary for all LM patients to clarify the etiology of the process, prevent recurrence and complications.

  • Open Access

    A somatostatin analogue and immunosuppressive therapy in the treatment of complex forms of chyloperitoneum and chylothorax in newborns and infants

    by A. S. Gurskaya, M. A. Sulavko, R. R. Bayazitov, И. Ви. Карнута, E. V. Ekimovskaya, O. N. Nakovkin, D. M. Akhmedova, A. A. Klepikova, R. A. Khagurov, N. V. Petrova, et al.

    Chyloperitoneum and chylothorax are rare conditions with high mortality rates whose optimal treatment strategy remains unclear. The aim of the study was to evaluate the results of chyloperitoneum and chylothorax treatment with a synthetic somatostatin analogue (octreotide) and immunosuppressive therapy with sirolimus. The study was approved by the Independent Ethics Committee and the Scientific Council of the National Medical Research Center for Children’s Health of Ministry of Healthсare of Russia. The patients' parents gave their consent to the use of their children's data, including photographs, for research purposes and in publications. We conducted a retrospective study of nine children diagnosed with congenital chyloperitoneum and chylothorax who had been treated from 2018 to 2022. All the children received either abdominal or pleural drainage, parenteral nutrition, and conservative therapy with drugs. The first line of therapy was octreotide for 14–20 days that was then switched to sirolimus if there had been no effect. The effectiveness of conservative therapy with octreotide at a dose of 5–10 µg/kg/hour was observed in 5 cases. If there had been no effect by day 14, the patients were started on sirolimus at a dose of 0.05–0.2 mg/day which proved to be effective in all the patients (n = 4). Our study showed that sirolimus is effective in complex cases of chyloperitoneum and chylothorax in newborns and infants. Because of the rarity of these disorders, our conclusions were based on the analysis of a small cohort. To confirm our results and develop uniform diagnostic and treatment guidelines, further, more targeted multicenter research is needed. Until such guidelines are adopted, decisions on the treatment of chyloperitoneum and chylothorax should be made on an individual basis and approved by the medical committee of a treatment center.

  • Open Access

    Diagnosis and treatment of esophageal lung in a premature baby

    by Abdumanap B. Alhasov, Alexandra S. Gurskaya, Oleg N. Nakovkin, Klavdiya A. Kazakova, Rimir R. Bayazitov, Sergey A. Ratnikov, Dinara M. Akhmedova, Marina A. Konovalenko, Mariya A. Varichkina, Inna V. Karnuta

    The esophageal lung is a rare congenital malformation of the foregut, characterized by the existence of the lung tissue, a segment of the lung, and the main bronchus between the esophagus and the part of respiratory system. Because of the rare occurrence of this defect, examples of the treatment of this disease can be found only in foreign literature, in Russian-language sources, there are no described cases of treatment of the esophageal lung. In this regard, the literature data was analyzed and there was presented, clinical picture, classification, diagnosis, and treatment of this defect, as well as a case from practical activities was carried out: diagnosis and treatment of a premature one month baby with an esophageal lung.